Empery Asset Management’s InMed Pharmaceuticals INM Stock Holding History

Empery Asset Management’s Portfolio INM Stock Details INM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-123	Closed	-$58K	–	77
2022 Q1	$58K	Buy	+123	New	+$64.5K	0.27%	44

Other funds holding INM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Empery Asset Management's INM Position: Q2 2022 in Review

Empery Asset Management sold out of InMed Pharmaceuticals (INM) in Q2 2022, closing a stake of 123 shares — an estimated $58K sold.

Empery Asset Management first reported a position in INM in Q1 2022 and held it in 1 quarter. The position peaked at $58K in Q1 2022. 11 funds tracked by Wall St. Rank hold INM as of Q2 2022.

Empery Asset Management reported no remaining InMed Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Empery Asset Management sold 123 InMed Pharmaceuticals shares in Q2 2022, an estimated $58K.
Empery Asset Management first reported a position in InMed Pharmaceuticals in Q1 2022 and held it in 1 quarter.
Empery Asset Management's InMed Pharmaceuticals position peaked at $58K in Q1 2022.
11 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q2 2022.

Based on Empery Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.